1999
Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification
Borchert G, Melegos D, Yu H, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis E. Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. Clinical Biochemistry 1999, 32: 39-44. PMID: 10074890, DOI: 10.1016/s0009-9120(98)00079-4.Peer-Reviewed Original ResearchImmunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou E, Levesque M, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis E. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Research 1999, 19: 749-56. PMID: 10216487.Peer-Reviewed Original ResearchConceptsP53 protein accumulationOvarian carcinomaP53 abnormalitiesP53 mutationsP53 proteinMissense point mutationsPrimary epithelial ovarian carcinomaEpithelial ovarian carcinomaGrade 3 lesionsCM-1 antibodyP53 protein overexpressionP53 exons 5Exon 5Unfavorable prognosisMutant p53 proteinP53 alterationsSerous histotypeClinical valueStage IIIDO-1Most malignanciesImmunofluorometric assayCarcinomaTumor tissueProtein accumulation
1996
Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies
Melegos D, Yu H, Allen L, Diamandis E. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clinical Biochemistry 1996, 29: 555-562. PMID: 8939403, DOI: 10.1016/s0009-9120(96)00093-8.Peer-Reviewed Original ResearchConceptsProstate-specific antigenSerum PSA concentrationAmniotic fluidPregnant womenFetal abnormalitiesPSA concentrationNonpregnant womenGestational ageHigher serum PSA concentrationsSerum prostate-specific antigenGestational week 15Gestational weeks 11Median PSA concentrationGestational weeks 13Gender of fetusesPSA levelsMaternal serumAbnormal pregnanciesMaternal ageRenal disordersLength of abstinenceWeek 13Week 15Diagnostic usefulnessTime-resolved immunofluorometric procedureCirculating antibodies against p53 protein in patients with ovarian carcinoma
Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsAntibody-positive patientsOvarian carcinomaP53 antibodiesP53 autoantibodiesPositive patientsSuch antibodiesMultivariate analysisPatient disease-free survivalKaplan-Meier survival curvesSerum p53 antibodiesTumor p53 overexpressionDisease-free survivalOlder patient ageSubset of patientsTumor histologic typeOverall patient survivalSera of patientsFrequent molecular eventUnits/LFree survivalNegative patientsOverall survivalPatient ageSuch autoantibodiesAntibody levelsUltrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samples
1995
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators
Levesque M, Clark G, Yu H, Diamandis E. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. British Journal Of Cancer 1995, 72: 720-727. PMID: 7545416, PMCID: PMC2033897, DOI: 10.1038/bjc.1995.400.Peer-Reviewed Original ResearchConceptsS-phase fractionEpidermal growth factor receptorHER-2/neuProgesterone receptorPrognostic indicatorBreast cancerBreast tumorsProstate-specific antigen expressionIndependent prognostic indicatorP53 proteinProstate-specific antigenAggressive tumor phenotypeWilcoxon rank sum analysisBreast tumor extractsStatus of p53Growth factor receptorPresence of PSARank-sum analysisFavorable prognosisPrognostic factorsBetter prognosisLevels of ERPresence of p53Antigen expressionTumor extractsQuantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumorsUltrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
Yu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.Peer-Reviewed Original ResearchMeSH KeywordsFluoroimmunoassayHumansMaleMicrochemistryNeoplasm Recurrence, LocalProstate-Specific AntigenProstatectomyProstatic NeoplasmsConceptsTumor-doubling timeProstate-specific antigenProstate cancer relapseRelapse-free periodRadical prostatectomyPSA assaysCancer relapseUltrasensitive prostate specific antigenProstate cancer patientsUltrasensitive assayExponential tumor growthPSA changeCancer patientsPatientsProstatectomyTumor growthEarly detectionRelapseAntigenAssaysBasis of criteriaDaysCystoprostatectomyPostsurgerySurgeryOriginal Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique
Yu H, Diamandis E. Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. Journal Of Urology 1995, 153: 1004-1008. PMID: 7531781, DOI: 10.1016/s0022-5347(01)67622-5.Peer-Reviewed Original ResearchConceptsSerum prostate-specific antigenProstate-specific antigenPSA levelsDetectable serum prostate specific antigenDistribution of PSAHigher serum prostate-specific antigenSerum prostate-specific antigen levelHealthy female blood donorsMeasurable prostate-specific antigenPostoperative prostate-specific antigenPreoperative prostate-specific antigenProstate-specific antigen levelYear of surgeryEvidence of relapseFemale blood donorsSpecific antigen levelsAge 50 yearsProstate cancer patientsHospitalized womenPatients 50Recurrent tumorsAntigen levelsHistological gradeCancer patientsRadical prostatectomyProstate-specific antigen immunoreactivity in amniotic fluid.
Yu H, Diamandis E. Prostate-specific antigen immunoreactivity in amniotic fluid. Clinical Chemistry 1995, 41: 204-210. PMID: 7533063, DOI: 10.1093/clinchem/41.2.204.Peer-Reviewed Original ResearchConceptsProtease prostate-specific antigenAmniotic fluidAlpha-fetoproteinGestational ageProstate-specific antigen immunoreactivitySensitive immunofluorometric procedureHigh alpha-fetoproteinHigher PSA concentrationsProstate-specific antigenNormal fetal developmentGrowth factor regulatorSerine protease prostate-specific antigenNonpregnant womenMaternal serumPregnant womenAntigen immunoreactivityBreast tumorsFetal developmentPSA concentrationImmunofluorometric procedurePregnancySignificant correlationWomenAgeSyndrome
1994
Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age
Yu H, Diamandis E, Sutherland D. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clinical Biochemistry 1994, 27: 75-79. PMID: 7520846, DOI: 10.1016/0009-9120(94)90015-9.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSAMale breast tumorsBreast tumor cytosolsBreast tumorsPatient agePositivity rateTumor cytosolsImmunoreactive prostate-specific antigenProstate-specific antigen levelPR-positive tumorsBreast cancer patientsSubset of tumorsCancerous prostatic tissueSteroid hormone receptorsAntigen levelsCancer patientsProgesterone receptorBreast cancerProstatic tissuePR actionEstrogenTumorsHormone receptorsSpecific markersQuantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer
Levesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigenPrognostic indicatorBreast cancerBreast tumorsBiochemical prognostic indicatorsCandidate prognostic indicatorBreast tumor cytosolsSteroid hormone receptorsNegative associationProgesterone receptorTumor cytosolsMutant p53 proteinTumor extractsP53 tumor suppressor gene productSpecific antigenBiochemical parametersObserved associationsHormone receptorsImmunofluorometric procedureStrong positive associationCognate steroid ligandP53 proteinReceptorsStrong negative associationTumor suppressor gene product
1993
Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies.
Yu H, Diamandis E. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clinical Chemistry 1993, 39: 2108-2114. PMID: 7691442, DOI: 10.1093/clinchem/39.10.2108.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseAntibodies, MonoclonalChromatography, High Pressure LiquidEdetic AcidFemaleFluoroimmunoassayHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstate-Specific AntigenProstatectomyProstatic NeoplasmsQuality ControlReference ValuesSensitivity and SpecificityTerbiumConceptsL PSAPolyclonal detection antibodyUltrasensitive time-resolved immunofluorometric assaySensitive prostate specific antigenPSA antibodyDetection antibodyTime-resolved fluorometryTime-resolved immunofluorometric assayUltrasensitive methodProstate-specific antigenMicrotiter wellsImmunofluorometric assayClinical applicationStreptavidinExtreme sensitivityAssays